Business, energy, technology, markets and global industry news from Business News Today

Ojemda

PharmaDeviceNews Ojemda
Representative image of a pediatric oncology consultation as Servier and Day One advance FIREFLY-2, a pivotal trial testing OJEMDA as a potential front-line treatment for BRAF-altered pediatric low-grade glioma.
Pharma & Biotech

Why Servier’s FIREFLY-2 enrollment milestone could reshape pediatric glioma treatment

OJEMDA is already approved after relapse. FIREFLY-2 asks whether Servier can move targeted pLGG therapy earlier.

Read More
Pharma & Biotech

Ipsen moves closer to EU approval for Ojemda in BRAF-driven childhood brain tumors

Ipsen nears EU approval for Ojemda in BRAF-driven pediatric glioma. Explore regulatory impact, clinical implications, and long-term risks.

Read More